ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake Supports Improved Outlook, RBC Says

MT Newswires Live08-06

ACADIA Pharmaceuticals' (ACAD) Daybue sales beat in Q2 due to the Stix formulation uptake on a better tolerability profile support an improved outlook, while Nuplazid to treat hallucinations linked with Parkinson's disease continues to perform solidly, RBC Capital Markets said in a research report emailed Wednesday.

An expected European Union launch in Q4 in Germany, followed by other countries, and with 60% of June US scripts being for Stix, could support 2026 sales of up to $500 million, according to the note.

The company's Remlifanserin to treat hallucinations related to Alzheimer's disease is now the near-term focal point, with trial enrolment complete and readout window narrowing, analysts wrote.

The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $37 per share from $36.

Price: 28.69, Change: +1.54, Percent Change: +5.67

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657529224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657529224","market":"hk","top_or_hot":-1,"title":"ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake  Supports Improved Outlook, RBC Says","media":"MT Newswires Live","content":"<html><body><p> ACADIA Pharmaceuticals' (ACAD) Daybue sales beat in Q2 due to the Stix formulation uptake on a better tolerability profile support an improved outlook, while Nuplazid to treat hallucinations linked with Parkinson's disease continues to perform solidly, RBC Capital Markets said in a research report emailed Wednesday.</p><p>An expected European Union launch in Q4 in Germany, followed by other countries, and with 60% of June US scripts being for Stix, could support 2026 sales of up to $500 million, according to the note.</p><p>The company's Remlifanserin to treat hallucinations related to Alzheimer's disease is now the near-term focal point, with trial enrolment complete and readout window narrowing, analysts wrote.</p><p>The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $37 per share from $36.</p><p>Price: 28.69, Change: +1.54, Percent Change: +5.67</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake  Supports Improved Outlook, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nACADIA Pharmaceuticals' Q2 Daybue Sales Beat on Stix Formulation Uptake  Supports Improved Outlook, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-06 00:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ACADIA Pharmaceuticals' (ACAD) Daybue sales beat in Q2 due to the Stix formulation uptake on a better tolerability profile support an improved outlook, while Nuplazid to treat hallucinations linked with Parkinson's disease continues to perform solidly, RBC Capital Markets said in a research report emailed Wednesday.</p><p>An expected European Union launch in Q4 in Germany, followed by other countries, and with 60% of June US scripts being for Stix, could support 2026 sales of up to $500 million, according to the note.</p><p>The company's Remlifanserin to treat hallucinations related to Alzheimer's disease is now the near-term focal point, with trial enrolment complete and readout window narrowing, analysts wrote.</p><p>The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $37 per share from $36.</p><p>Price: 28.69, Change: +1.54, Percent Change: +5.67</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACAD","symbol_name":"阿卡迪亚","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657529224","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657529224","pubTimestamp":1785948908,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ACADIA Pharmaceuticals'  Daybue sales beat in Q2 due to the Stix formulation uptake on a better tolerability profile support an improved outlook, while Nuplazid to treat hallucinations linked with Parkinson's disease continues to perform solidly, RBC Capital Markets said in a research report emailed Wednesday.An expected European Union launch in Q4 in Germany, followed by other countries, and with 60% of June US scripts being for Stix, could support 2026 sales of up to $500 million, according to the note.The company's Remlifanserin to treat hallucinations related to Alzheimer's disease is now the near-term focal point, with trial enrolment complete and readout window narrowing, analysts wrote.The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $37 per share from $36.Price: 28.69, Change: +1.54, Percent Change: +5.67","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ACAD":"阿卡迪亚"},"translate_title":"加拿大皇家银行表示，ACADIA Pharmaceuticals 第二季度 Daybue 销售额因 Stix 配方的采用而超出预期，支持了前景的改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAD":1.5},"content_text":"ACADIA Pharmaceuticals' (ACAD) Daybue sales beat in Q2 due to the Stix formulation uptake on a better tolerability profile support an improved outlook, while Nuplazid to treat hallucinations linked with Parkinson's disease continues to perform solidly, RBC Capital Markets said in a research report emailed Wednesday.An expected European Union launch in Q4 in Germany, followed by other countries, and with 60% of June US scripts being for Stix, could support 2026 sales of up to $500 million, according to the note.The company's Remlifanserin to treat hallucinations related to Alzheimer's disease is now the near-term focal point, with trial enrolment complete and readout window narrowing, analysts wrote.The brokerage said it reiterated its outperform rating on the stock and boosted its price target to $37 per share from $36.Price: 28.69, Change: +1.54, Percent Change: +5.67","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657529224","isCrawlerRequest":true}